Streetbeat News

Price Targets

TSX:OPS

RBC Capital analyst Douglas Miehm has reiterated an Outperform rating on Opsens (TSX:OPS) and maintained a price target of C$3.5.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:34 pm

LNT

Barclays analyst Eric Beaumont has maintained an Overweight rating on Alliant Energy (NASDAQ:LNT) but lowered the price target from $55 to $51.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:28 pm

TFX

Stephens & Co. analyst George Sellers has reiterated an Overweight rating on Teleflex (NYSE:TFX) and maintained a price target of $315.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:26 pm

OLN

Barclays analyst Michael Leithead has downgraded Olin (NYSE:OLN) from Overweight to Equal-Weight and lowered the price target from $60 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:26 pm

CERT

Stephens & Co. analyst Jeff Garro has reiterated an Overweight rating on Certara (NASDAQ:CERT) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:23 pm

FAF

Stephens & Co. analyst John Campbell has reiterated an Overweight rating on First American Financial (NYSE:FAF) and maintained a $72 price target.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:22 pm

BALL

Barclays analyst Michael Leithead has upgraded Ball Corporation (NYSE:BALL) from Equal-Weight to Overweight and lowered the price target from $61 to $59.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:19 pm

RGLD

BMO Capital analyst Jackie Przybylowski has maintained a 'Market Perform' rating on Royal Gold (NASDAQ:RGLD) and raised the price target from $137 to $139.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:17 pm

TSX:FOM

BMO Capital analyst Rene Cartier maintains an Outperform rating on Foran Mining and raises the price target from C$4.75 to C$5.25.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:15 pm

OLMA

HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:46 am